True Leaf Engages Boustead Securities to Underwrite Regulation A+ Offering

Donnerstag, 12.10.2017 13:05 von DGAP - Aufrufe: 199

DGAP-News: True Leaf Medicine International Inc. / Key word(s): Miscellaneous True Leaf Engages Boustead Securities to Underwrite Regulation A+ Offering 12.10.2017 / 13:00 The issuer is solely responsible for the content of this announcement.


Vancouver, British Columbia--(Newsfile Corp. - October 12, 2017) - True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) ('True Leaf'), a company involved in the hemp and cannabis-based product industry, has filed a preliminary offering circular with the Securities and Exchange Commission ('SEC') pursuant to the Regulation A framework, which is open to both accredited and unaccredited investors.

True Leaf has engaged Boustead Securities, LLC Member: FINRA/SIPC ('Boustead'), as lead underwriter. 'Boustead looks forward to working with True Leaf's team to bring their Regulation A+ offering to investors,' commented David Dobkin of Boustead.

'We are pleased to have Boustead leading the effort,' said True Leaf CEO Darcy Bomford, 'their expertise in Regulation A has proven successful in the past.'

The purpose of the filing is to issue new shares of common stock to raise gross proceeds of up to $10 million CAD to help grow the True Leaf Pet division, and to advance the efforts of the True Leaf Medicine division with the goal of becoming a licensed producer of medicinal cannabis in Canada. Once its Regulation A+ offering has been qualified by the SEC, the offering will be made available to the general public to invest in True Leaf.

About True Leaf

True Leaf Medicine International Ltd., through its wholly owned subsidiary 'True Leaf Pet', has entered the global pet industry, forecast to reach $117 billion US in 20211, with a line of hemp-focused pet supplements in Canada, the United States and Europe. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer of medical cannabis through its 'True Leaf Medicine' subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada's review and has recently received approval to build its facility.

www.trueleaf.com

Media Contact:

Paul Sullivan Director, Public Relations Paul@trueleaf.com O: 604-685-4742 M: 604-603-7358

Investor Contact:

Kevin Bottomley Director and Corporate Relations Kevin@trueleaf.com M: 778-389-9933

About Boustead Securities, LLC Member: FINRA/SIPC

Boustead Securities, LLC is an investment banking firm that advises clients on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions. Our core value proposition is our ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

SEC Legends

An offering statement regarding this offering has been filed with the SEC. Once the SEC has qualified the offering statement True Leaf Medicine International Ltd. may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a preliminary copy of the offering circular that is part of that offering statement HERE. You should read the offering circular before making any investment.

Forward-Looking Statements

This news release contains forward-looking statements and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we refer you to a more detailed discussion of the risks and uncertainties in the Company's filings with the Securities and Exchange Commission when available. The forward-looking statements contained in this news release are made only as of today, and True Leaf Medicine International Ltd. is under no obligation to revise or update these forward-looking statements.

1http://www.petfoodindustry.com/articles/6458-pet-care-market-forecast-to-hit-us117-billion-in-2021?v=preview

newsinfo.php?i=29635&f=169

Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/29635

12.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language: English
Company: True Leaf Medicine International Inc.
Canada
ISIN: CA89785C1077
 
End of News DGAP News Service

618363  12.10.2017 

fncls.ssp?fn=show_t_gif&application_id=618363&application_name=news&site_id=ariva
Werbung

Mehr Nachrichten kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.




Kurse

0,0136 $
-32,0%
Maven Brands Inc Chart